Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Targeted hepatitis C drug launched in UK

  • Comment

A hepatitis C drug, which is the first to specifically target the disease, has been launched in Britain.

Licensed treatments for hepatitis C have previously focused solely on boosting the immune system to fight the infection, but clinical trials have now revealed that adding Victrelis to treatment boosted the number of patients cured of the disease by up to three times.

One of a number of drugs referred to as protease inhibitors, Victrelis is different because it attacks the virus directly.

Chief executive of the the Hepatitis C Trust Charles Gore said: “The infection is known as the “silent epidemic” because it may take decades to produce any symptoms. Ultimately, the virus can cause serious liver damage or liver cancer.

“Current therapy can fail some patients, but the arrival of a new class of drugs will mean more people will be able to clear the virus.”

It is thought that as many as 216,000 people in the UK have chronic hepatitis C but many do not know they are infected.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.